{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:24:11Z","timestamp":1790029451703,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40273-023-01281-8","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T17:02:02Z","timestamp":1686330122000},"page":"1011-1025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-9110","authenticated-orcid":false,"given":"Aurelie","family":"Meunier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Longworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeram","family":"Ramagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis P.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"1281_CR1","unstructured":"NICE. NICE glossary: health inequities. https:\/\/www.nice.org.uk\/glossary?letter=h#:~:text=A%20health%20inequity%20is%20an,person%2C%20and%20that%20of%20another. Accessed 18 July 2022."},{"key":"1281_CR2","unstructured":"WHO. Health Equity. https:\/\/www.who.int\/health-topics\/health-equity#tab=tab_1. Accessed 18 July 2022."},{"key":"1281_CR3","doi-asserted-by":"crossref","unstructured":"Meunier A, Longworth L, Kowal S, Ramagopalan S, Love-Koh J, Griffin S. Distributional cost-effectiveness analysis of health technologies: data requirements and challenges Value Health. 2022(In Press).","DOI":"10.1016\/j.jval.2022.06.011"},{"issue":"5","key":"1281_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1017\/S0266462318000508","volume":"34","author":"CA Bellemare","year":"2018","unstructured":"Bellemare CA, Dagenais P, Suzanne K, B\u00e9land J-P, Bernier L, Daniel C-\u00c9, et al. Ethics in health technology assessment: a systematic review. Int J Technol Assess Health Care. 2018;34(5):447\u201357. https:\/\/doi.org\/10.1017\/S0266462318000508.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"1281_CR5","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462320002275","volume":"37","author":"M Benkhalti","year":"2021","unstructured":"Benkhalti M, Espinoza M, Cookson R, Welch V, Tugwell P, Dagenais P. Development of a checklist to guide equity considerations in health technology assessment. Int J Technol Assess Health Care. 2021;37(1): e17. https:\/\/doi.org\/10.1017\/S0266462320002275.","journal-title":"Int J Technol Assess Health Care."},{"key":"1281_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780198838197.001.0001","volume-title":"Distributional cost-effectiveness analysis: quantifying health equity impacts and trade-offs","author":"R Cookson","year":"2020","unstructured":"Cookson R, Griffin S, Norheim OF, Culyer AJ. Distributional cost-effectiveness analysis: quantifying health equity impacts and trade-offs. Oxford: Oxford University Press; 2020."},{"key":"1281_CR7","unstructured":"Department of Health and Social Care. New era of public health to tackle inequalities and level up the UK. https:\/\/www.gov.uk\/government\/news\/new-era-of-public-health-to-tackle-inequalities-and-level-up-the-uk. Accessed 11 February 2022."},{"key":"1281_CR8","unstructured":"Public Health Agency of Canada. Health Inequalities in Canada: A National Portrait. Executive Summary. Ottawa, ON: Public Health Agency of Canada; 2018."},{"key":"1281_CR9","unstructured":"Sant\u00e9 publique France. Les in\u00e9galit\u00e9s sociales et territoriales de sant\u00e9. https:\/\/www.santepubliquefrance.fr\/les-inegalites-sociales-et-territoriales-de-sante#block-344919. Accessed 11 February 2022."},{"issue":"16","key":"1281_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.socscimed.2016.10.022","volume":"170","author":"RA Cookson","year":"2016","unstructured":"Cookson RA. Equity-informative health technology assessment: a commentary on Ngalesoni, Ruhago, Mori Robberstad & Norheim. Soc Sci Med. 2016;170(16):218\u20139. https:\/\/doi.org\/10.1016\/j.socscimed.2016.10.022.","journal-title":"Soc Sci Med"},{"key":"1281_CR11","unstructured":"NICE. The NICE strategy 2021 to 2026. London: National Institute for Health and Care Excellence; 2021."},{"key":"1281_CR12","volume-title":"CHTE methods review: equalities: task and finish group report","author":"L Dunning","year":"2020","unstructured":"Dunning L, Owens R, Owen L, Southall S, Carter K, Lamb A, et al. CHTE methods review: equalities: task and finish group report. London: National Institute for Health and Care Excellence; 2020."},{"issue":"6","key":"1281_CR13","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/hec.3058","volume":"24","author":"M Asaria","year":"2015","unstructured":"Asaria M, Griffin S, Cookson R, Whyte S, Tappenden P. Distributional cost-effectiveness analysis of health care programmes\u2013a methodological case study of the UK bowel cancer screening programme. Health Econ. 2015;24(6):742\u201354.","journal-title":"Health Econ"},{"issue":"3","key":"1281_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/heapol\/czx175","volume":"33","author":"BR Dawkins","year":"2018","unstructured":"Dawkins BR, Mirelman AJ, Asaria M, Johansson KA, Cookson RA. Distributional cost-effectiveness analysis in low-and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia. Health Policy Plan. 2018;33(3):456\u201363. https:\/\/doi.org\/10.1093\/heapol\/czx175.","journal-title":"Health Policy Plan"},{"issue":"5","key":"1281_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hec.4003","volume":"29","author":"S Griffin","year":"2020","unstructured":"Griffin S, Walker S, Sculpher M. Distributional cost effectiveness analysis of West Yorkshire low emission zone policies. Health Econ. 2020;29(5):567\u201379. https:\/\/doi.org\/10.1002\/hec.4003.","journal-title":"Health Econ"},{"key":"1281_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2020.113339","volume":"265","author":"J Love-Koh","year":"2020","unstructured":"Love-Koh J, Pennington B, Owen L, Taylor M, Griffin S. How health inequalities accumulate and combine to affect treatment value: a distributional cost-effectiveness analysis of smoking cessation interventions. Soc Sci Med. 2020;265: 113339. https:\/\/doi.org\/10.1016\/j.socscimed.2020.113339.","journal-title":"Soc Sci Med"},{"issue":"5","key":"1281_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jval.2019.03.006","volume":"22","author":"J Love-Koh","year":"2019","unstructured":"Love-Koh J, Cookson R, Gutacker N, Patton T, Griffin S. Aggregate distributional cost-effectiveness analysis of health technologies. Value Health. 2019;22(5):518\u201326. https:\/\/doi.org\/10.1016\/j.jval.2019.03.006.","journal-title":"Value Health."},{"key":"1281_CR18","unstructured":"NICE. Technology appraisal data: appraisal recommendations 2022. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\/data\/appraisal-recommendations. Accessed 18 July 2022."},{"key":"1281_CR19","unstructured":"NICE. Technology appraisal data: cancer appraisal recommendations 2022. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\/data\/cancer-appraisal-recommendations. Accessed 18 July 2022."},{"key":"1281_CR20","unstructured":"NCRAS. Lung cancer cases in England 2019. https:\/\/www.cancerdata.nhs.uk\/incidence_and_mortality. Accessed 2 September 2021."},{"key":"1281_CR21","unstructured":"Ministry of Housing Communities & Local Government. English indices of deprivation 2012. https:\/\/www.gov.uk\/government\/collections\/english-indices-of-deprivation. Accessed 2 September 2021."},{"key":"1281_CR22","unstructured":"NICE. Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy [TA520] 2018. https:\/\/www.nice.org.uk\/guidance\/ta520. Accessed 18 July 2022."},{"key":"1281_CR23","unstructured":"NICE. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer [TA536] 2018. https:\/\/www.nice.org.uk\/guidance\/ta536. Accessed 18 July 2022."},{"key":"1281_CR24","unstructured":"Office for National Statistics. Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2020. 2021. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/annualmidyearpopulationestimates\/mid2020. Accessed 23 August 2022."},{"key":"1281_CR25","unstructured":"Office for National Statistics. Population by Index of Multiple Deprivation (IMD), England, 2001 to 2019. 2020. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/adhocs\/12386populationbyindexofmultipledeprivationimdengland2001to2019. Accessed 23 August 2022."},{"key":"1281_CR26","unstructured":"NICE. Resource impact report: alectinib for untreated anaplastic lymphoma kinase-positive advanced nonsmall-cell lung cancer (TA536) 2018. https:\/\/www.nice.org.uk\/guidance\/ta536\/resources\/resource-impact-report-pdf-4911618349. Accessed 18 July 2022."},{"key":"1281_CR27","unstructured":"NICE. Resource impact report: atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520) 2018. https:\/\/www.nice.org.uk\/guidance\/ta520\/resources\/resource-impact-report-pdf-4845749149. Accessed 2 September 2021."},{"key":"1281_CR28","unstructured":"NCRAS. National Disease Registration Service: staging data in England. https:\/\/www.cancerdata.nhs.uk\/stage_at_diagnosis. Accessed 18 July 2022."},{"issue":"5","key":"1281_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jval.2015.03.1784","volume":"18","author":"J Love-Koh","year":"2015","unstructured":"Love-Koh J, Asaria M, Cookson R, Griffin S. The social distribution of health: estimating quality-adjusted life expectancy in England. Value Health. 2015;18(5):655\u201362. https:\/\/doi.org\/10.1016\/j.jval.2015.03.1784.","journal-title":"Value Health."},{"issue":"2","key":"1281_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/0272989X20904360","volume":"40","author":"J Love-Koh","year":"2020","unstructured":"Love-Koh J, Cookson R, Claxton K, Griffin S. Estimating social variation in the health effects of changes in health care expenditure. Med Decis Making. 2020;40(2):170\u201382. https:\/\/doi.org\/10.1177\/0272989X20904360.","journal-title":"Med Decis Making"},{"key":"1281_CR31","volume-title":"Comparing smoking cessation to screening and brief intervention for alcohol in distributional cost effectiveness analysis to explore the sensitivity of results to socioeconomic inequalities characterised in model inputs","author":"F Yang","year":"2021","unstructured":"Yang F, Angus C, Duarte AI, Gillespie D, Sculpher M, Walker SM, et al. Comparing smoking cessation to screening and brief intervention for alcohol in distributional cost effectiveness analysis to explore the sensitivity of results to socioeconomic inequalities characterised in model inputs. Centre for Health Economics: University of York; 2021."},{"issue":"3","key":"1281_CR32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/0022-0531(70)90039-6","volume":"2","author":"AB Atkinson","year":"1970","unstructured":"Atkinson AB. On the measurement of inequality. J Econ Theory. 1970;2(3):244\u201363.","journal-title":"J Econ Theory."},{"issue":"10","key":"1281_CR33","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/hec.3430","volume":"26","author":"M Robson","year":"2017","unstructured":"Robson M, Asaria M, Cookson R, Tsuchiya A, Ali S. Eliciting the level of health inequality aversion in England. Health Econ. 2017;26(10):1328\u201334. https:\/\/doi.org\/10.1002\/hec.3430.","journal-title":"Health Econ"},{"issue":"14","key":"1281_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19140","volume":"19","author":"K Claxton","year":"2015","unstructured":"Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1\u2013503. https:\/\/doi.org\/10.3310\/hta19140.","journal-title":"Health Technol Assess"},{"key":"1281_CR35","unstructured":"Department of Health and Social Care. Updating the statutory scheme controlling the costs of branded health service medicines. 2022."},{"key":"1281_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101771","volume":"67","author":"G Rait","year":"2020","unstructured":"Rait G, Horsfall L. Twenty-year sociodemographic trends in lung cancer in non-smokers: A UK-based cohort study of 3.7 million people. Cancer Epidemiol. 2020;67: 101771.","journal-title":"Cancer Epidemiol."},{"issue":"3\u20134","key":"1281_CR37","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1475-5890.2016.12109","volume":"37","author":"R Cookson","year":"2016","unstructured":"Cookson R, Propper C, Asaria M, Raine R. Socio-economic inequalities in health care in England. Fisc Stud. 2016;37(3\u20134):371\u2013403.","journal-title":"Fisc Stud"},{"key":"1281_CR38","unstructured":"Cancer Research UK. Cancer incidence for common cancers 2021. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence\/common-cancers-compared#heading-Five. Accessed 18 July 2022."},{"issue":"5","key":"1281_CR39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/hec.864","volume":"13","author":"N Devlin","year":"2004","unstructured":"Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437\u201352. https:\/\/doi.org\/10.1002\/hec.864.","journal-title":"Health Econ"},{"issue":"7","key":"1281_CR40","doi-asserted-by":"publisher","first-page":"A335","DOI":"10.1016\/j.jval.2015.09.113","volume":"18","author":"L Versoza","year":"2015","unstructured":"Versoza L, Jaksa A, Liden D, Ho Y. Do evidence review groups bias NICE decisions? Value Health. 2015;18(7):A335.","journal-title":"Value Health."},{"issue":"1","key":"1281_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6963-11-8","volume":"11","author":"C Donaldson","year":"2011","unstructured":"Donaldson C, Baker R, Mason H, Jones-Lee M, Lancsar E, Wildman J, et al. The social value of a QALY: raising the bar or barring the raise? BMC Health Serv Res. 2011;11(1):1\u20138.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1281_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1478-7547-12-18","volume":"12","author":"OF Norheim","year":"2014","unstructured":"Norheim OF, Baltussen R, Johri M, Chisholm D, Nord E, Brock D, et al. Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis. Cost Effect Resour Allocat. 2014;12(1):1\u20138.","journal-title":"Cost Effect Resour Allocat."},{"key":"1281_CR43","unstructured":"NICE. NICE health technology evaluations: the manual London: National Institute for Health and Care Excellence; 2022."},{"key":"1281_CR44","unstructured":"NICE. NICE guide to the methods of technology appraisal. London: National Institute for Health and Care Excellence; 2013."},{"key":"1281_CR45","unstructured":"ISPOR. Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions. https:\/\/www.ispor.org\/conferences-education\/education-training\/webinars\/webinar\/distributional-cost-effectiveness-analysis-to-inform-healthcare-decisions. Accessed 18 July 2022."},{"key":"1281_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.socscimed.2015.10.005","volume":"146","author":"Y Gu","year":"2015","unstructured":"Gu Y, Lancsar E, Ghijben P, Butler JR, Donaldson C. Attributes and weights in health care priority setting: a systematic review of what counts and to what extent. Soc Sci Med. 2015;146:41\u201352.","journal-title":"Soc Sci Med"},{"issue":"11","key":"1281_CR47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/jme.2009.032102","volume":"36","author":"K Sharkey","year":"2010","unstructured":"Sharkey K, Gillam L. Should patients with self-inflicted illness receive lower priority in access to healthcare resources? Mapping out the debate. J Med Ethics. 2010;36(11):661\u20135. https:\/\/doi.org\/10.1136\/jme.2009.032102.","journal-title":"J Med Ethics"},{"key":"1281_CR48","unstructured":"ONS. Likelihood of smoking four times higher in England\u2019s most deprived areas than least deprived 2018. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/drugusealcoholandsmoking\/articles\/likelihoodofsmokingfourtimeshigherinenglandsmostdeprivedareasthanleastdeprived\/2018-03-14. Accessed 08\/02\/2023."},{"key":"1281_CR49","unstructured":"ASH. Health Inequalities and Smoking. 2019."},{"issue":"1","key":"1281_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1377\/hlthaff.2020.02054","volume":"40","author":"AD Paltiel","year":"2021","unstructured":"Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical outcomes of a COVID-19 vaccine: Implementation over efficacy. Health Aff (Millwood). 2021;40(1):42\u201352.","journal-title":"Health Aff (Millwood)."},{"key":"1281_CR51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jhealeco.2017.06.005","volume":"57","author":"G Moscelli","year":"2018","unstructured":"Moscelli G, Siciliani L, Gutacker N, Cookson R. Socioeconomic inequality of access to healthcare: Does choice explain the gradient? J Health Econ. 2018;57:290\u2013314.","journal-title":"J Health Econ"},{"key":"1281_CR52","unstructured":"NCRAS. Cancer registration statistics, England 2019. Published October 2021. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cancer-registration-statistics\/england-2019. Accessed 18 July 2022."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01281-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01281-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01281-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:11:30Z","timestamp":1744715490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01281-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1281"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01281-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"11 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aurelie Meunier and Louise Longworth are employees at PHMR. PHMR received financial support from F. Hoffmann-La Roche Ltd for the work, including the analysis and preparation of the manuscript. Sreeram Ramagopalan was an employee of F. Hoffmann-La Roche Ltd\u00a0at the time of the study, who funded the work. Manuel Gomes, Louis P. Garrison and Sanjay Popat have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"PHMR received financial support from F. Hoffmann-La Roche Ltd to conduct this study and prepare the manuscript. Louis P. Garrison received financial support as a subcontractor to PHMR.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Please contact the corresponding author for any requests for any study materials including codes.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AM: Study conception and design, data analysis and interpretation, drafting of the manuscript. LL: Study conception and design, data analysis and interpretation, critical revision of the paper for important intellectual content, supervision. SR: Critical revision of the paper for important intellectual content, obtaining funding, supervision. MG, LG, SP: Critical revision of the paper for important intellectual content.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}